RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors

510(k) Device May Improve Targeted Delivery of Chemotherapy LOS ALTOS, Calif., Sept. 7, 2021 -- (Healthcare Sales &Marketing Network) -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announc... Devices, Drug Delivery, Oncology, FDA RenovoRx, RenovoCath Delivery System, RenovoGem, RenovoTAMP
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractBreast cancer is the most common cancer among women in terms of prevalence and mortality, and chemotherapy is one of the most effective treatments at higher stages. However, resistance to chemotherapy is the main obstacle in the treatment of this cancer. Accumulated evidence identified the PD-L1 protein as an essential protein in the development of different cancers. Abnormal expression of this protein in various tumor cells is linked to cancer development and inhibiting the function of immune cells, which correlated with reduced beneficial effects of chemotherapy drugs. In the present study, the effects of common ...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Mol Biol Rep. 2021 Oct 20. doi: 10.1007/s11033-021-06752-9. Online ahead of print.ABSTRACTCancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment br...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Source Type: research
This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The objective of this review was to analyze the results from preclinical and clinical trials of these drugs for the treatment of cancer. Sphingolipid-targeting drugs have been tested alone or in combination with chemotherapy, exhibiting antitumor activity alone and in synergism with chemotherapy in vitro and in vivo. As a consequence of treatments, the most frequent mechanism of cell death is apoptosis, followed by autophagy. Aslthough all these drugs have produced good results in preclinical studies of multiple cancers, the outcomes of clinical trials have not been similar. The most effective drugs are fenretinide and &al...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractCurrent cancer therapies aim at eradicating cancer cells from the body. However, killing cells generates cell “debris” which can promote tumor progression. Thus, therapy can be a double-edged sword. Specifically, injury and debris generated by cancer therapies, including chemotherapy, radiation, and surgery, may offset their benefit by promoting the secretion of pro-tumorigenic factors (e.g., eicosanoid -driven cytokines) that stimulate regrowth and metastasis of surviving cells. The debris produced by cytotoxic cancer therapy can also contribute to a tumor microenvironment that promotes tumor progressi...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
CONCLUSION: In this review, we discuss the mechanisms of EGFR-TKIs drug resistance and the clinical strategies to overcome drug resistance from the perspective of EGFR-TKIs combined treatment.PMID:34661758 | DOI:10.1007/s00432-021-03828-8
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractConsidering that conventional chemotherapy provides only a limited increase of overall survival for patients with colorectal cancer (CRC), and resistance is a major cause of therapeutic failure, the emergence of new therapies is needed. Development of different compounds is based on molecular hybridization, which constitutes an effective strategy to inhibit cancer cells and overcome cancer drug resistance. For this purpose, a novel series of chalcone- and melatonin- based hybrids (6a –h) was designed, synthesized, and evaluated for the cytotoxic and antiproliferative effect against SW480 human colon cancer ce...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Free Radic Biol Med. 2021 Oct 14:S0891-5849(21)00761-9. doi: 10.1016/j.freeradbiomed.2021.10.013. Online ahead of print.ABSTRACTIncreasing evidence suggests the significant contribution of high levels of thioredoxin reductase (TrxR) in various stages of tumorigenesis and resistance to tumor chemotherapy. Thus, inhibition of TrxR with small molecules is an attractive strategy for cancer therapy. Eriocalyxin B (EriB), a naturally occurring diterpenoid extracted from Isodon eriocalyx, has reflected potential anticancer activities through numerous pathways. Here, we describe that EriB covalently modifies GSH and selectively in...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Source Type: research
In conclusion, CRISPR/Cas9 could be a major step forward to cancer management by providing patients with an effective method for dealing with cancers by dissecting the carcinogenesis pathways, identifying new biologic targets, and perhaps arming cancer cells with drugs. Hence, this review will discuss the current applications of CRISPR/Cas9 technology in tumor angiogenesis research for the purpose of cancer treatment.PMID:34655593 | DOI:10.1016/j.ijbiomac.2021.10.029
Source: International Journal of Biological Macromolecules - Category: Biochemistry Authors: Source Type: research
Biomed Pharmacother. 2021 Nov;143:112248. doi: 10.1016/j.biopha.2021.112248. Epub 2021 Sep 30.ABSTRACTMoringa oleifera, Tropaeolum tuberosum and Annona cherimola are medicinal plants traditionally used in Ecuador. However, their therapeutic properties are not completely known. We analyzed chromatographically ethanolic extracts of the seeds of M. oleifera, A. cherimola and the tubers of T. tuberosum; all presented a high content of polyphenols. The extract of A. cherimola showed the highest antioxidant activity and M. oleifera had the highest capacity to enhance the activity of detoxifying enzymes such as glutathione S-tran...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Marketing | Pharmaceuticals